News

Atossa Therapeutics Welcomes Claudia Lopez as New VP for Clinical Development

Atossa Therapeutics Welcomes Claudia Lopez as New VP for Clinical Development

Atossa Therapeutics Welcomes Claudia Lopez as New VP for Clinical Development

Atossa Therapeutics, Inc. (NASDAQ: ATOS) is excited to announce the recent appointment of Claudia Lopez, DVM, MSc, as its Vice President of Clinical Product Development. As a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for breast cancer, Atossa is poised for a significant advancement in its clinical endeavors.

Claudia Lopez: A Proven Leader in Clinical Development

Dr. Lopez joins Atossa with over two decades of rich experience in clinical development, emphasizing formidable leadership roles in global programs spanning immunology, oncology, and metabolic disorders. Her impressive history includes her recent position as Vice President of Clinical Development at Landos Biopharma, where she led international clinical strategies and ensured regulatory compliance for successful clinical trials.

Driving Clinical Strategies to Success

Throughout her career, Dr. Lopez has excelled in navigating complex clinical landscapes. She has a proven track record of guiding innovative treatments from initial development stages to successful regulatory outcomes. Her strategic insight will enhance Atossa’s clinical pipeline, particularly in advancing next-generation therapies for breast cancer.

Atossa's Commitment to Transformative Cancer Treatments

Dr. Steven Quay, Chief Executive Officer of Atossa Therapeutics, expressed enthusiasm about the appointment, saying, “We are thrilled to welcome Dr. Lopez to the Atossa team. Her in-depth knowledge of clinical development and her strategic vision are pivotal to our mission of delivering transformative treatments for breast cancer.” Her leadership is expected to significantly influence the direction of Atossa’s clinical programs as they strive to enhance patient outcomes across various stages of treatment.

Dr. Lopez’s Diverse Experience Across Major Pharma Companies

Dr. Lopez has amassed a wealth of experience through her roles in leading organizations like Arena Pharmaceuticals and Takeda Pharmaceuticals, where she made substantial contributions to clinical program management. Her experience includes orchestrating multidisciplinary teams, directing regulatory submissions both in the United States and Europe, and overseeing extensive clinical development initiatives in numerous therapeutic areas.

Vision for the Future: Realizing Atossa's Potential

“I am honored to be joining Atossa at a time when the company is poised for significant growth,” stated Dr. Lopez. She is enthusiastic about leveraging her experience to push forward the innovative therapies within Atossa’s pipeline. The potential for clinical advancements in breast cancer is exciting, and Dr. Lopez is dedicated to making strides in the development of these essential treatments.

About Atossa Therapeutics

Atossa Therapeutics, Inc. specializes in developing cutting-edge medicines aimed at addressing significant unmet medical needs in oncology. With a particular focus on (Z)-endoxifen, Atossa is dedicated to exploring both prevention and treatment avenues for breast cancer. Their commitment to patient care and innovative solutions is at the core of their mission.

Contact Information

For more inquiries, the company's public relations can be reached through Michael Parks, VP Investor and Public Relations at 484-356-7105 or michael.parks@atossainc.com.

Frequently Asked Questions

What role has Claudia Lopez been appointed to at Atossa Therapeutics?

Claudia Lopez has been named Vice President of Clinical Product Development at Atossa Therapeutics.

What is Atossa Therapeutics focused on?

Atossa Therapeutics is focused on developing innovative therapies for breast cancer, particularly using (Z)-endoxifen.

What are Dr. Lopez's previous roles?

Dr. Lopez previously served as Vice President of Clinical Development at Landos Biopharma and held positions at Arena Pharmaceuticals and Takeda Pharmaceuticals.

Why is Dr. Lopez's appointment significant for Atossa?

Her extensive clinical development experience and strategic expertise are expected to significantly advance Atossa’s pipeline and treatment offerings for breast cancer patients.

How can I learn more about Atossa Therapeutics?

For more information about Atossa Therapeutics and their clinical developments, you can visit their official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sinopec Unveils Biodiversity Report at COP17

Updated Category News Views 65

Sinopec's First Step on the Global Biodiversity Stage Seems like Sinopec (HKG: 0386) has decided to toss its hat into the biodiversity conservation ring. At COP17 in Armenia, they released their inaugural Global Biodiversity Conservation Report—an event that marks more than just a company selling oil and gas. Now, they're talking wildlife and ecologies. Is that irony,...

Continue Reading
NumbersGame's Bold Integration Ups the Accounting Ante

Updated Category News Views 24

Integrating the Heavy Hitters: Stripe, Square, and Ramp Diving headfirst into the mix, NumbersGame's recent move to open up integration with heavyweights like Stripe, Square, and Ramp is nothing short of a game-changer for accountants in the field. If you’re an accounting firm handling multiple clients, brace yourself—these latest enhancements might just redefine the...

Continue Reading
Fresha Teams with Klarna: Shaking Up Beauty Payments

Updated Category News Views 126

New Flexibility at the Beauty Checkout Hey, if you've ever paced back and forth considering signing up for that luxury self-care spree, well, Fresha’s latest move might just tip the scales. The beauty and wellness booking giant has partnered with Klarna, diving headfirst into the Buy Now, Pay Later (BNPL) craze. It's about time, right? Everyone loves a good spa session,...

Continue Reading
Oracle's $20 Billion Offering: What Investors Need to Know

Updated Category News Views 14

Oracle's Big Play: A $20 Billion Offering Nobody said playing in the big leagues was easy, and Oracle seems to be doubling down on that idea. Today, they spilled the beans on their ambition to rake in a cool $20 billion through an offering of common stock and senior notes. For those of us who keep a close eye on NYSE:ORCL, this is more than just a number—it's a signal...

Continue Reading
TriMas Streamlines Portfolio with Rapak Sale

Updated Category News Views 48

TriMas Sheds Rapak: A Strategic Move Here's a twist worth dissecting: TriMas Corporation (NASDAQ: TRS) has offloaded its subsidiary Rapak, LLC to the German industrial packaging giant, Ringmetall SE. This isn't just a business shuffle—it's a calculated pivot with eyes on sharpening the core business blade. As they announced from Bloomfield Hills, Michigan, this move...

Continue Reading
Platinum Equity's Bold Move on Warren Valve: An Analysis

Updated Category News Views 51

A Big Play in the Valve Game Straight out of the industrial playbook, Platinum Equity swoops in with its latest acquisition of Warren Valve, yanking it from the clutches of Allied Group. It's not every day you see a move like this in the flow control world. Yeah, you heard that right—flow control. The kind of business that’s all about ensuring the right stuff gets to...

Continue Reading
Extreme Weather Survivors Rally for Change with 'Stolen Summers'

Updated Category News Views 62

Lighting a Fire Under Complacency Elections often bring out the big dogs, but rarely do you see a grassroots campaign like Extreme Weather Survivors’ 'Stolen Summers' making such ripples. Rallying from New York to North Carolina and everywhere in between, this campaign has been a clarion call for communities ravaged by Mother Nature's fury. And let's face it, the...

Continue Reading
Clarivate Integrates Trademark Data with Microsoft AI

Updated Category News Views 61

You know, the market's all abuzz with AI this, AI that. But today, we're getting a glimpse at something that isn't just hyped-up vaporware; it's actually useful. Clarivate Plc (NYSE:CLVT), which has carved a niche in transformative intelligence, is teaming up with Microsoft to slide their CompuMark trademark data into Microsoft Copilot via something they call IPOne. It's...

Continue Reading
Ascletis Showcases Bold Moves in Obesity Drug Arena

Updated Category News Views 174

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

Continue Reading
Immunic's November Moves: Conferences and Clinical Trials

Updated Category News Views 87

Immunic Taps Into November Conferences Every now and then, you catch a company that's not just spinning its wheels but making some potentially big waves in their field. This time, it's Immunic, Inc. (Nasdaq: IMUX), stepping into the spotlight. They're strutting their stuff at several investor conferences this November, starting with Boston and New York, then hopping over...

Continue Reading

Top 5 Most Recently Viewed Articles

Feedzai Unveils TRUST Framework for Ethical AI Development

Updated Category News Views 203

Feedzai Introduces Innovative TRUST Framework Feedzai, a leading global provider of risk management solutions, recently introduced its pioneering TRUST Framework at the HumanX conference. This framework is designed to equip B2B organizations with a comprehensive approach to developing ethical, secure, and high-performing generative AI solutions. As businesses increasingly...

Continue Reading
Lotus Technology Welcomes New Leadership for Growth and Innovation

Updated Category News Views 364

Lotus Technology's Leadership Changes Signal New Directions Lotus Technology Inc. (“Lotus” or the “Company”) (Nasdaq: LOT), a prominent global player in intelligent and luxury mobility solutions, is making significant strides in its leadership approach. The company recently announced important changes in its management team and board of directors, marking an...

Continue Reading
Trella Health Empowers Post-Acute Care Decision-Making

Updated Category News Views 153

Launching a New Era in Post-Acute Care This initiative is designed to empower strategic, data-driven decisions for post-acute organizations. Trella Health, the leading provider of market intelligence and integrated customer relationship management solutions for post-acute care, is launching its "Optimize for Outcomes" content series. This new series aims to empower...

Continue Reading
Brown & Root Achieves Notable Safety Award with Innovative Hydration System

Updated Category News Views 142

Brown & Root's Remarkable Achievement in Safety Standards Brown & Root, a leader in industrial services, has recently received the esteemed Best-In-Class Award at the Annual Safety Excellence Awards. This accolade, presented by the Industry Business Roundtable and Health and Safety Council, underscores the company's unwavering dedication to safety and innovation. The...

Continue Reading
Understanding the Boom of the Cannabis Edibles Market Leaders

Updated Category News Views 270

Cannabis Edibles: A Market Growing at Full Speed The cannabis edibles market has surged in recent years as more people choose to consume cannabis without smoking. As this shift takes hold, brands such as Wyld, Incredibles, Wana, and Kiva have emerged as reliable, widely recognized names, shaping expectations for taste, consistency, and experience in a fast-expanding...

Continue Reading